COLLECTIONS
WORKFLOWS
Recent Finacing
Recent Raise
Cargo Therapeutics engineers CAR T-cell therapies using a proprietary platform that incorporates therapeutic cargo, developing an autologous CD22 CAR T candidate (CRG-022) for relapsed/refractory LBCL and discovery-stage programs.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
